NCT02431572View on ClinicalTrials.gov

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Intracranial TumorsGlioblastomaMelanoma
Interventions
OTHER

PBR PET

BIOLOGICAL

Cancer Immunotherapy

Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.

RADIATION

Radiation and chemotherapy

Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.

Trial Locations (2)

02215

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT02431572 - A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy | Biotech Hunter | Biotech Hunter